PMID- 12616696
OWN - NLM
STAT- MEDLINE
DCOM- 20030702
LR  - 20191106
IS  - 1127-0020 (Print)
IS  - 1127-0020 (Linking)
VI  - 6
IP  - 3
DP  - 2002 Sep
TI  - Allogeneic stem cell transplantation for multiple myeloma.
PG  - 205-24
AB  - The sensitivity of myeloma cells to high dose chemotherapy has led to the use of 
      allogeneic hematopoietic stem cell transplantation (HSCT) as a therapeutic 
      modality in this disease. In addition to providing more effective chemotherapy, 
      the transplantation of allogeneic stem cells also initiates the development of an 
      allogeneic immune response directed against residual myeloma cells. Direct 
      evidence for a graft vs. myeloma (GVM) effect is provided by the ability of donor 
      lymphocyte infusion (DLI) to induce significant responses in 30-50% of patients 
      with myeloma who have relapsed after allogeneic HSCT. Nevertheless, allogeneic 
      stem cell transplantation is also associated with a high incidence of transplant 
      related toxicities, including regimen-related toxicities, graft vs. host disease 
      (GVHD) and opportunistic infections. DLI has been shown to enhance immune 
      reconstitution after allogeneic HSCT in addition to inducing a GVM response. 
      Current efforts are directed at reducing the toxicities associated with 
      allogeneic HSCT, identification of the target antigens of GVM and the development 
      of new strategies to selectively enhance the immune response to myeloma cells.
FAU - Bellucci, Roberto
AU  - Bellucci R
AD  - Center for Hematologic Oncology, Dana-Farber Cancer Institute, Department of 
      Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Ritz, Jerome
AU  - Ritz J
LA  - eng
GR  - AI29530/AI/NIAID NIH HHS/United States
GR  - CA78378/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Italy
TA  - Rev Clin Exp Hematol
JT  - Reviews in clinical and experimental hematology
JID - 9815344
SB  - IM
MH  - Graft vs Tumor Effect
MH  - Hematopoietic Stem Cell Transplantation/adverse effects/*methods
MH  - Humans
MH  - Lymphocyte Transfusion
MH  - Multiple Myeloma/*therapy
MH  - Transplantation Conditioning/methods
MH  - Transplantation Immunology
MH  - Transplantation, Homologous
RF  - 90
EDAT- 2003/03/06 04:00
MHDA- 2003/07/03 05:00
CRDT- 2003/03/06 04:00
PHST- 2003/03/06 04:00 [pubmed]
PHST- 2003/07/03 05:00 [medline]
PHST- 2003/03/06 04:00 [entrez]
AID - 10.1046/j.1468-0734.2002.00075.x [doi]
PST - ppublish
SO  - Rev Clin Exp Hematol. 2002 Sep;6(3):205-24. doi: 
      10.1046/j.1468-0734.2002.00075.x.